Premium
The landscape of psoriasis provision in the UK
Author(s) -
Smith S. P.,
Mohd Mustapa M. F.,
Berker D.
Publication year - 2020
Publication title -
clinical and experimental dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.587
H-Index - 78
eISSN - 1365-2230
pISSN - 0307-6938
DOI - 10.1111/ced.14286
Subject(s) - nice , excellence , psoriasis , audit , medicine , context (archaeology) , population , disease , health care , family medicine , intensive care medicine , dermatology , business , environmental health , economic growth , political science , geography , pathology , accounting , archaeology , computer science , economics , law , programming language
Summary Psoriasis remains one of the commonest conditions seen in dermatological practice, and its treatment is one of the greatest cost burdens for the UK National Health Service. Treatment of psoriasis is complex, with numerous overlapping lines and therapies used in combination. This complexity reflects the underlying pathophysiology of the disease as well as the heterogeneous population that it affects. National Institute for Health and Care Excellence (NICE) guidance for the treatment of psoriasis has been available since 2013, and has been the subject of three national audits conducted by the British Association of Dermatologists. This report synthesizes the results of the most recent of those exercises and places it in the context of the NICE guidance and previous audits. It clearly shows the significant burden of disease, issues with provision of services and long waiting times and the marked shift in therapies towards targeted biologic therapies.